<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/'><id>tag:blogger.com,1999:blog-2744263723545918621.post5335796382195734344..comments</id><updated>2009-03-02T13:25:16.120-08:00</updated><title type='text'>Comments on Uremic Frost: Vascular Access Controversies</title><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://www.uremicfrost.com/feeds/5335796382195734344/comments/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2744263723545918621/5335796382195734344/comments/default'/><link rel='alternate' type='text/html' href='http://www.uremicfrost.com/2009/02/vascular-access-controversies.html'/><author><name>Dr. Simon E. Prince, FACP, FASN</name><uri>http://www.blogger.com/profile/03460983023759293165</uri><email>sprince@nsneph.com</email></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>2</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-2744263723545918621.post-2244504596255628451</id><published>2009-03-02T13:25:16.120-08:00</published><updated>2009-03-02T13:25:16.120-08:00</updated><title type='text'>Such a distinguished guest... I am honored, Dr App...</title><content type='html'>Such a distinguished guest... I am honored, Dr Appell. Thank you for your contribution to the field of Nephrology.. as well as for taking the time to comment here.</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/2744263723545918621/5335796382195734344/comments/default/2244504596255628451'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2744263723545918621/5335796382195734344/comments/default/2244504596255628451'/><link rel='alternate' type='text/html' href='http://www.uremicfrost.com/2009/02/vascular-access-controversies.html?showComment=1236029116120#c2244504596255628451' title=''/><author><name>Dr. Simon E. Prince, FACP, FASN</name><uri>http://www.blogger.com/profile/03460983023759293165</uri><email>noreply@blogger.com</email><gd:extendedProperty xmlns:gd='http://schemas.google.com/g/2005' name='OpenSocialUserId' value='03887623512399907796'/></author><thr:in-reply-to xmlns:thr='http://purl.org/syndication/thread/1.0' href='http://www.uremicfrost.com/2009/02/vascular-access-controversies.html' ref='tag:blogger.com,1999:blog-2744263723545918621.post-5335796382195734344' source='http://www.blogger.com/feeds/2744263723545918621/posts/default/5335796382195734344' type='text/html'/></entry><entry><id>tag:blogger.com,1999:blog-2744263723545918621.post-4666959703924390961</id><published>2009-03-02T13:11:41.719-08:00</published><updated>2009-03-02T13:11:41.719-08:00</updated><title type='text'>As the originator of the peripheral A-V fistula, I...</title><content type='html'>As the originator of the peripheral A-V fistula, I agree in general with your comments.&lt;BR/&gt;&lt;BR/&gt;The peripheral A-V fistula is the best method for chronic vascular access.  We can anticipate &lt;BR/&gt;10 to 20 to 30 years or more of use from an A-V fistula.&lt;BR/&gt;&lt;BR/&gt;However there are instances where an A-V fistula would not be indicated.  &lt;BR/&gt;&lt;BR/&gt;In patients with multiple or severe co-morbidity that may be life- threatening it would not be indicated.  Other means are available for dialysis.  After all, an A-V fistulla requires an operative procedure.  &lt;BR/&gt;&lt;BR/&gt;The A-V fistula is designed for long-term use.  Patients requiring short term dialysis are best treated by central lines.&lt;BR/&gt;&lt;BR/&gt;The question of closure of an A-V fistula following a successful kidney transplant would depend upon the particular patient.  If the fistula is not unsightly we should consider keeping it as a backup.  Fistulas are well tolerated and do not detract from the transplant.&lt;BR/&gt;&lt;BR/&gt;In general, as in all good medicine, the therapy should be designed to fit the patient and not visa versa.  &lt;BR/&gt;&lt;BR/&gt;Kenneth Charles Appell, MD&lt;BR/&gt;www.KennethAppellMD.com</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/2744263723545918621/5335796382195734344/comments/default/4666959703924390961'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2744263723545918621/5335796382195734344/comments/default/4666959703924390961'/><link rel='alternate' type='text/html' href='http://www.uremicfrost.com/2009/02/vascular-access-controversies.html?showComment=1236028301719#c4666959703924390961' title=''/><author><name>Kenneth Charles Appell</name><uri>http://www.kennethappellmd.com</uri><email>noreply@blogger.com</email></author><thr:in-reply-to xmlns:thr='http://purl.org/syndication/thread/1.0' href='http://www.uremicfrost.com/2009/02/vascular-access-controversies.html' ref='tag:blogger.com,1999:blog-2744263723545918621.post-5335796382195734344' source='http://www.blogger.com/feeds/2744263723545918621/posts/default/5335796382195734344' type='text/html'/></entry></feed>